Quick Answer
Larimar Therapeutics, Inc. reported Total Assets of $145.84 million for the year ending 2025.
- Larimar Therapeutics, Inc. showed a decrease of -27.2% in Total Assets from 2024 to 2025.
- This data is from Larimar Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2014: $136.97 million | Q3 2014: $129.64 million | Q1 2015: $236.72 million | Q2 2015: $222.60 million | Q3 2015: $207.45 million | Q1 2016: $170.03 million | Q2 2016: $154.83 million | Q3 2016: $142.71 million | Q1 2017: $119.37 million | Q2 2017: $108.85 million | Q3 2017: $96.26 million | Q1 2018: $92.61 million | Q2 2018: $79.80 million | Q3 2018: $131.95 million | Q1 2019: $110.19 million | Q2 2019: $103.88 million | Q3 2019: $92.89 million | Q1 2020: $73.70 million | Q2 2020: $125.46 million | Q3 2020: $113.96 million | Q1 2021: $93.02 million | Q2 2021: $80.93 million | Q3 2021: $87.94 million | Q1 2022: $71.22 million | Q2 2022: $62.85 million | Q3 2022: $133.02 million | Q1 2023: $118.91 million | Q2 2023: $111.72 million | Q3 2023: $103.95 million | Q1 2024: $248.21 million | Q2 2024: $237.16 million | Q3 2024: $219.02 million | Q1 2025: $170.18 million | Q2 2025: $149.99 million | Q3 2025: $187.35 million.
- Over the full 13 years of available data (2013 to 2025), Larimar Therapeutics, Inc.'s Total Assets has grown by 282.4%.
- Historical annual values: Fiscal year 2025: $145.84 million | Fiscal year 2024: $200.23 million | Fiscal year 2023: $95.94 million | Fiscal year 2022: $126.41 million | Fiscal year 2021: $78.67 million | Fiscal year 2020: $104.69 million | Fiscal year 2019: $5.20 million | Fiscal year 2018: $121.76 million | Fiscal year 2017: $105.51 million | Fiscal year 2016: $131.62 million | Fiscal year 2015: $189.11 million | Fiscal year 2014: $117.52 million | Fiscal year 2013: $38.14 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: